Tonix Pharmaceuticals stock halted ahead of FDA approval news
Investing.com - TD Cowen has reduced its price target on Target (NYSE:TGT) to $100.00 from $105.00 while maintaining a Hold rating on the stock. According to InvestingPro data, Target , currently valued at $47.69 billion, appears undervalued based on its Fair Value analysis.
The firm expects Target’s second-quarter earnings per share to come in at $1.95, below the Street consensus and 5 cents lower than its previous estimate, citing anticipated weaker comparable sales. The company is scheduled to report these results on August 20.
TD Cowen projects Target’s comparable sales to decline by 3.5%, worse than the Street’s expected 3.0% drop, with EBIT margin decreasing by 140 basis points compared to the Street’s 120 basis points forecast, primarily due to lower flowthrough amid discretionary spending pressures.
Despite these concerns, the firm notes that Target’s fiscal 2026 price-to-earnings valuation now stands at 13x, with the stock having gained 15% following the first-quarter earnings miss and reduced full-year guidance, after which fiscal 2026 EPS estimates were cut by 3%. Currently trading at a P/E of 11.45x and offering a 4.34% dividend yield, Target presents interesting metrics for value investors. Get deeper insights into Target’s valuation with InvestingPro, which offers exclusive analysis and 8 additional ProTips about the company.
TD Cowen interprets this stock performance as investors positioning for a "better-than-feared" scenario, suggesting that Target could reiterate its full-year guidance even with a second-quarter miss.
In other recent news, Target has been the focus of several analyst updates and ratings. Truist Securities raised its price target for Target to $107 from $90, maintaining a Hold rating, citing better-than-expected second-quarter sales performance. UBS reiterated its Buy rating with a price target of $135, ahead of Target’s second-quarter earnings report, noting market expectations of a slight decline in comparable sales. Meanwhile, Bernstein maintained an Underperform rating with a price target of $86, highlighting potential turnaround challenges for the company.
Additionally, Fitch Ratings affirmed Target’s Long-Term Issuer Default Rating at ’A’, with a Negative outlook due to recent execution missteps and industry volatility. Bernstein SocGen Group also increased its price target to $86 from $80, expecting slightly better top-line performance than anticipated. These developments indicate diverse perspectives on Target’s financial health and future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.